Quantcast

Latest Response Evaluation Criteria in Solid Tumors Stories

2014-07-24 08:33:44

Based on encouraging progression-free survival data, Lpath extends the study to a second cohort and considers additional proof-of-concept studies SAN DIEGO, July 24, 2014 /PRNewswire/ -- Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, reported interim results in a Phase 2a single-arm, open-label trial where ASONEP(TM) is being investigated as a treatment for metastatic renal cell carcinoma (RCC) in patients that have failed at least one...

2014-06-25 20:22:13

NEW YORK, June 25, 2014 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Endocyte, Inc. ("Endocyte" or the "Company") (NASDAQ: ECYT) concerning whether the board has breached its fiduciary duties to shareholders or violated the federal securities laws. http://photos.prnewswire.com/prnvar/20120215/MM54604LOGO For years Endocyte has been conducting studies of a therapy for ovarian cancer called "RECIST." In March...

2014-05-29 08:30:55

Company Reported Positive Preliminary Responses in Phase I/II Trial Patients; Feuerstein Falsely Claims There Is No Positive Trial Information BETHESDA, Md., May 29, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, refuted the latest blatantly false and misleading statements made by Adam Feuerstein, in an article on Tuesday, May 27....

2014-01-13 08:29:57

CAMBRIDGE, Mass., Jan. 13, 2014 /PRNewswire/ -- Cerulean Pharma Inc., a leader in dynamically tumor-targeted nanopharmaceuticals, today announced that CRLX101 has achieved its primary efficacy endpoint in an ongoing single-arm Phase 2 monotherapy clinical trial in relapsed ovarian cancer. The ongoing open label Phase 2 monotherapy trial is being conducted at Massachusetts General Hospital and the affiliated Harvard teaching hospitals under the direction of principal investigator,...

2013-04-26 11:58:17

New scoring system defines patients who achieve most benefit from TACE Data from a number of clinical trials presented today at the International Liver Congress 2013 shed new light on the use of TACE and SIRT in the treatment of hepatocellular carcinoma (HCC). Transarterial chemoembolization (TACE) is a technique in which small particles designed to block blood vessels mixed or coated with chemotherapeutic drugs are injected directly into an artery supplying the tumor; it has become a...

2010-09-10 11:45:04

Cancer immunotherapy calls for revised clinical endpoints that differ from those used for chemotherapy, according to an article published online September 8 in The Journal of the National Cancer Institute. Unlike chemotherapy, which acts directly on tumors, cancer immunotherapies exert their effects on the immune system, which may delay or change response patterns, perhaps owing to the dynamics of the immune system itself. For example, initial tumor burden may increase due to lymphocytic...

2010-07-07 16:59:41

Optics Express publishes special focus issue highlighting lung cancer imaging research Advanced imaging technologies that promise to improve the development of effective drugs to treat lung cancer are the focus of the current special issue of Optics Express (http://www.opticsinfobase.org/oe), an open-access journal published by the Optical Society (OSA). Research featured in the special focus issue on Imaging in Diagnosis and Treatment of Lung Cancer...

2009-01-20 09:53:32

The first, formal revision of specific guidelines, known as RECIST, used by clinicians to measure tumor size and response to treatment, has been published today (Tuesday 20 January) in a special issue of the European Journal of Cancer. The authors say that the revisions will ease the workload involved in running clinical trials, without compromising study outcomes. RECIST (Response Evaluation Criteria in Solid Tumors) were first published in 2000 and are used by investigators in phase II and...

2008-07-02 09:00:13

TUSTIN, Calif., July 2 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. today reported that its lead product candidate bavituximab achieved the pre-specified Stage 1 primary endpoint in its ongoing Phase II clinical trial in patients with metastatic breast cancer. The trial is an open-label, Simon two-stage design to evaluate the safety and efficacy of a combination of bavituximab and docetaxel in metastatic breast cancer patients. Fourteen of the 15 patients enrolled in Stage 1...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related